Vineet Laboratories Limited (BOM:543298)

Market Cap	726.19M +118.8%
Revenue (ttm)	560.13M -43.4%
Net Income	-101.39M
EPS	-11.04
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	95,128
Open	39.81
Previous Close	38.96
Day's Range	37.67 - 39.81
52-Week Range	28.00 - 51.84
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 25, 2026

About Vineet Laboratories

Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and fine chemicals primarily in India. The company offers intermediates of Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates. It also provides fine chemicals and reagents, such as isopropyl-beta-d-thiogalactopyranoside, n-butyl lithium, 4-nitrophenyl phosphate disodium salt, 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside, 5-acetyl th...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 2016
• Employees: 57
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543298

Financial Performance

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 23, 2026

Data Sources Report a data error